Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.19−1.16 (-10.22%)
Close on Nov 12, 2026Market cap $655.77MP/E –Yield –
Cullinan Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cullinan Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$218.52M. For fiscal 2025 it was -$241.34M. The highest annual figure on record is $144.74M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$241.34M | – |
| FY2024 | Dec 31, 2024 | -$196.61M | – |
| FY2023 | Dec 31, 2023 | -$190.78M | -231.8% |
| FY2022 | Dec 31, 2022 | $144.74M | – |
| FY2021 | Dec 31, 2021 | -$67.90M | – |
| FY2020 | Dec 31, 2020 | -$60.27M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$52.55M | – |
| Q2 FY2026 | Jun 30, 2026 | -$57.18M | – |
| Q1 FY2026 | Mar 31, 2026 | -$53.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$55.18M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.52M | – |
| Q2 FY2025 | Jun 30, 2025 | -$75.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.92M | – |
| Q4 FY2024 | Dec 31, 2024 | -$54.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$48.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$49.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$42.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$45.16M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.52M | -115.7% |
| Q1 FY2023 | Mar 31, 2023 | -$62.68M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.76M | – |
| Q2 FY2022 | Jun 30, 2022 | $239.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$32.64M | -2453.6% |
| Q4 FY2021 | Dec 31, 2021 | -$34.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.59M | – |
| Q1 FY2021 | Mar 31, 2021 | $1.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$29.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.53M | – |
See a number that looks wrong?